Clinical Trial Update: A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled study evaluated BI 1356 in patients with Type 2 diabetes who cannot take metformin, with an 18-week treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BI 1356 (BI 1356)
• Glimepiride (glimepiride)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2011-10-26